Last reviewed · How we verify
Ultra-Long GnRH Agonists
Ultra-long GnRH agonists provide sustained suppression of gonadotropin-releasing hormone signaling, leading to prolonged inhibition of luteinizing hormone and follicle-stimulating hormone release.
Ultra-long GnRH agonists provide sustained suppression of gonadotropin-releasing hormone signaling, leading to prolonged inhibition of luteinizing hormone and follicle-stimulating hormone release. Used for Prostate cancer (androgen deprivation therapy), Endometriosis, Uterine fibroids.
At a glance
| Generic name | Ultra-Long GnRH Agonists |
|---|---|
| Sponsor | University of Palermo |
| Drug class | GnRH agonist |
| Target | GnRH receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology; Endocrinology |
| Phase | FDA-approved |
Mechanism of action
These agents bind to GnRH receptors and provide extended pharmacological activity through modified formulations or delivery systems, resulting in continuous suppression of the hypothalamic-pituitary-gonadal axis. This leads to sustained reduction in sex hormone production (testosterone and estrogen), with effects lasting weeks to months per dose. The ultra-long duration distinguishes them from conventional GnRH agonists by reducing dosing frequency and improving patient compliance.
Approved indications
- Prostate cancer (androgen deprivation therapy)
- Endometriosis
- Uterine fibroids
- Precocious puberty
Common side effects
- Hot flashes
- Decreased libido
- Erectile dysfunction
- Injection site reactions
- Headache
- Fatigue
- Bone density loss
Key clinical trials
- Does The Addition Of Letrozole To Ultra-Long GnRH Agonists Help Adenomyosis Patients in ART? The AURA Trial (PHASE4)
- Adenomyosis and ART (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ultra-Long GnRH Agonists CI brief — competitive landscape report
- Ultra-Long GnRH Agonists updates RSS · CI watch RSS
- University of Palermo portfolio CI